Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.
1 |
Andriole G et al. |
The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
|
2 |
Atalay M et al. |
Treatments with sodium selenate or doxycycline offset diabetes-induced perturbations of thioredoxin-1 levels and antioxidant capacity.
|
3 |
Belch JJF et al. |
The Scottish-Finnish-Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia.
|
4 |
Buvat J et al. |
Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study).
|
5 |
Carlsson SV et al. |
No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer.
|
6 |
Chapple CR et al. |
Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
|
7 |
Cropp CD et al. |
Genome-wide linkage scan for prostate cancer susceptibility in Finland: evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22.
|
8 |
Fizazi K et al. |
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
|
9 |
Haillot O et al. |
The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study.
|
10 |
Hedlund PO et al. |
Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer.
|
11 |
Huuskonen A et al. |
Common genetic variation in the IGF1 associates with maximal force output.
|
12 |
Kemppainen KJ et al. |
The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case-control study.
|
13 |
Kilpeläinen TP et al. |
False-positive screening results in the European randomized study of screening for prostate cancer.
|
14 |
Kokk K et al. |
Expression of luteinizing hormone receptors in the mouse penis.
|
15 |
Koskela VK et al. |
Peripheral arterial disease in octogenarians and nonagenarians: factors predicting survival.
|
16 |
Kote-jarai Z et al. |
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.
|
17 |
Kuorilehto T et al. |
Marfanin oireyhtymään, Ehlers-Danlosin oireyhtymään ja neurofibromatoosi 1:een liittyvät verisuonimuutokset ja niiden kirurginen hoito.
|
18 |
Mattila H et al. |
NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene.
|
19 |
Melkas S et al. |
Small-vessel disease relates to poor poststroke survival in a 12-year follow-up.
|
20 |
Murtola T et al. |
Comparative effects of high and low-dose simvastatin on prostate epithelial cells: The role of LDL.
|
21 |
Mäkelä E et al. |
Magnetic resonance imaging of acute scrotum.
|
22 |
Nickel JC et al. |
Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
|
23 |
Pekkarinen T et al. |
Aikuisen oireeton mikroskooppinen verivirtsaisuus.
|
24 |
Pogodin-Hannolainen D et al. |
Prostate cancer screening: a survey of attitudes and practices among Finnish physicians in 1999 and 2007.
|
25 |
Pöllänen P, Tammela T. |
Andrologiset lääkkeet.
|
26 |
Raitoharju E et al. |
miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study.
|
27 |
Raitoharju E et al. |
Common variation in the ADAM8 gene affects serum sADAM8 concentrations and the risk of myocardial infarction in two independent cohorts.
|
28 |
Rantanen T et al. |
Altered expression of HSP27 and HSP70 in distal oesophageal mucosa in patients with gastro-oesophageal reflux disease subjected to fundoplication.
|
29 |
Rantanen T et al. |
The impact of fibrin glue in the prevention of failure after nissen fundoplication.
|
30 |
Rantanen T et al. |
The effect of fundoplication on proliferative and anti-apoptotic activity of esophageal mucosa in gastroesophageal reflux disease: 4-year follow-up study.
|
31 |
Rantanen T et al. |
Proliferative and anti-apoptotic activity of esophageal mucosa in gastroesophageal reflux disease is not affected by fundoplication: a 4-year follow-up study.
|
32 |
Salenius J-P, Uurto I. |
Subclavian steal -oireyhtymä.
|
33 |
Salenius JP et al. |
Valtimoperäiset ääreisverenkierron häiriöt.
|
34 |
Shalaby A et al. |
Aquaporin-7 expression during coronary artery bypass grafting with Diazoxide.
|
35 |
Siltanen S et al. |
Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.
|
36 |
Smith MR et al. |
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer.
|
37 |
Suominen V. |
Onko diabeetikon jalkojen verenkierto riittävä.
|
38 |
Tammela T. |
Seulonnalla voidaan vähentää eturauhassyövän aiheuttamia kuolemia.
|
39 |
Tammela T. |
Virtsasuihkun heikkous ja Virtsaumpi.
|
40 |
Tammela T. |
Akuutti bakteeriperäinen eturauhastulehdus.
|
41 |
Tammela T. |
Eturauhasen liikakasvu.
|
42 |
Tammela T. |
Virtsarakon katetrointi ja subrapubinen kystostomia.
|
43 |
Tammela T. |
Krooninen eturauhastulehdus.
|
44 |
Tikkinen KAO et al. |
Lower urinary tract symptoms in adults treated for posterior urethral valves in childhood: matched cohort study.
|
45 |
Tolonen TT et al. |
Routine dual-color immunostaining with a 3-antibody cocktail improves the detection of small cancers in prostate needle biopsies.
|
46 |
Tolonen TT et al. |
Overall and worst gleason scores are equally good predictors of prostate cancer progression.
|
47 |
Tolonen TT et al. |
Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer.
|
48 |
Turpeinen H et al. |
Proprotein convertases in human atherosclerotic plaques: the overexpression of FURIN and its substrate cytokines BAFF and APRIL.
|
49 |
Turunen U, Jussila A. |
Krooniset tulehdukselliset suolistosairaudet.
|
50 |
Tähtinen RM et al. |
Smoking and bladder symptoms in women.
|
51 |
Vaarala M et al. |
Kastraation luustovaikutukset eturauhassyöpäpotilailla.
|
52 |
Vaarala M et al. |
Virtaa virtsaamiseen, watteja valumiseen.
|
53 |
Vaarala MH et al. |
Sacral neuromodulation in urological indications: the Finnish experience.
|
54 |
Vaughan CP et al. |
The Prevalence of Clinically Meaningful Overactive Bladder: Bother and Quality of Life Results from the Population-Based FINNO Study.
|
55 |
Venermo MA et al. |
EVAR may reduce the risk of aneurysm rupture despite persisting type ia endoleaks.
|
56 |
Wahlfors T et al. |
Identification of an aggressive prostate cancer predisposing variant at 11q13.
|